Open Beta
TREN
MetriLume
TREN

US marketsBRTX

SEC-sourced researchBeta

BRTX

BioRestorative Therapies, Inc.

Company comparison ↗

Data passport

CIK
0001505497
Exchange
Nasdaq
Business activity
— · SIC 8090
Financial inputs
5/6
Filing date
Sep 11, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 401,000.0000 USD; December 2025: 359,700.0000 USD401K USD0 USD0December 2024December 2025
BRTX · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2024401,000.0000Mar 26, 2026
December 2025359,700.0000Mar 26, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025359,700.0000-14,241,975.0000-10,788,963.00004,079,635.0000—Mar 26, 2026
December 2024401,000.0000-8,979,381.0000-8,230,346.000012,279,799.0000—Mar 26, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$359.7KDecember 2025Mar 26, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$401KDecember 2024Mar 26, 202610-K
Net incomeNetIncomeLoss-$14.24MDecember 2025Mar 26, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$10.79MDecember 2025Mar 26, 202610-K
Total assetsAssets$4.08MDecember 2025Mar 26, 202610-K
Total liabilities————

New filings

Explore methodology ↗